Navigation Links
Pacira Pharmaceuticals, Inc. Adds Board Member and Key Senior Management
Date:7/9/2008

SAN DIEGO, July 9 /PRNewswire/ -- Pacira Pharmaceuticals, Inc., an acute care specialty pharmaceutical company, today announced the appointment of a new Board member and the addition of a key senior executive to the company's management team. Gary Pace, Ph.D, joins the Board of Directors as a seasoned biopharmaceutical executive with more than 30 years of experience. Dr. Pace brings his development and commercial experience to Pacira as the founder and past Chairman and CEO of QRx Pharma Ltd (ASX: QRX), as well as holding director and chairman positions for several specialty pharmaceutical companies. Bill Kirkpatrick, Ph.D. joins Pacira as Vice President, Compliance. Dr. Kirkpatrick brings 30 years of medical regulatory and quality assurance experience to Pacira. He has been instrumental in leading several product approvals through the FDA for both specialty pharmaceutical and medical device companies including; Artes Medical, Baxter, Chiron Ophthalmics, and ICN Pharmaceucticals.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070618/PACIRALOGO)

Dr. Pace joins Pacira's six existing Board members, including Chairman Fred Middleton, Sanderling Ventures; Luke Evnin, Ph.D., MPM Capital; Carl Gordon, Ph.D., Orbimed; John P. Longenecker, Ph.D., Favrille; Dave Stack, Pacira President and CEO; and Andreas Wicki, HBM Partners.

Pacira President and CEO Dave Stack stated, "Bill and Gary bring outstanding experience and leadership to Pacira. We expect their contributions to enhance the development and commercialization of DepoBupivacaine(TM) for post-surgical pain as well as advance our clinical pipeline of DepoFoam(R) technology-based products. With the expertise resident in our Board and our management team, we are well positioned to grow our proprietary product portfolio and our company, and thereby build significant value for patients, partners and all our stakeholders."

About Pacira

Pacira is an acute care specialty pharmaceutical company with a primary focus on developing products which satisfy the needs of our customers in the institutional marketplace. The Company utilizes DepoFoam(R) delivery technology to cost-effectively improve patient care through enhanced dosing and administration profiles. Currently, the Company is developing DepoBupivacaine(TM) in phase III clinical studies for postsurgical pain. Revenues are generated from two approved products which are marketed by partners: DepoCyt(R) for lymphomatous meningitis and DepoDur(R) for post-surgical pain. Additional information about Pacira is available at http://www.pacira.com.

This press release contains forward looking statements, which involve risks and uncertainties within the meaning of the Private Securities Litigation Reform Act of 1995. There can be no assurance that actual results will not differ materially from the forward looking statements discussed in this press release. These forward looking statements include risks and uncertainties that current or future collaboration will prove to be commercially successful.


'/>"/>
SOURCE Pacira Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pacira Pharmaceuticals, Inc. Expands Development Collaborations for DepoFoam(R)
2. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
3. Prestwick Pharmaceuticals, Inc. Continues to Build Management Team With Appointment of Martin Stogniew, Ph.D. as Executive Vice President, Chief Technology Officer
4. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
5. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
6. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
7. NPS Pharmaceuticals, Inc. Announces an Increase in Tender Offer Price for Its 3.0% Convertible Notes Due 2008 and Extends Expiration Date Until October 17, 2007
8. Alseres Pharmaceuticals, Inc. to Present at Bio Investor Forum 2007 Annual Meeting
9. Jazz Pharmaceuticals, Inc. Announces Changes to its Board of Directors
10. Alseres Pharmaceuticals, Inc. to Present at Windhovers Therapeutic Area Partnerships Conference
11. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... operations for Amgen, will join the faculty of the University of North ... adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... ... June 23, 2016 , ... UAS LifeSciences, ... launch of their brand, UP4™ Probiotics, into Target stores nationwide. The company, which ... to add Target to its list of well-respected retailers. This list includes such ...
(Date:6/23/2016)... June 23, 2016 Houston Methodist Willowbrook ... Cy-Fair Sports Association to serve as their official ... Houston Methodist Willowbrook will provide sponsorship support, athletic ... with association coaches, volunteers, athletes and families. ... Cy-Fair Sports Association and to bring Houston Methodist ...
Breaking Biology Technology:
(Date:5/16/2016)... --  EyeLock LLC , a market leader of iris-based ... IoT Center of Excellence in Austin, Texas ... embedded iris biometric applications. EyeLock,s iris authentication ... with unmatched biometric accuracy, making it the most proven ... platform uses video technology to deliver a fast and ...
(Date:5/9/2016)... -- Elevay is currently known as the ... high net worth professionals seeking travel for work   ... there is still no substitute for a face-to-face meeting. ... deal with a firm handshake. This is why wealthy ... citizenship via investment programs like those offered by the ...
(Date:4/28/2016)... SAN FRANCISCO and BANGALORE, India ... part of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... service provider, today announced a global partnership that ... convenient way to use mobile banking and payment services. ... Mobility is a key innovation area for financial services, but ...
Breaking Biology News(10 mins):